Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.48 USD
−192.41 M USD
0.00 USD
88.93 M
About Cogent Biosciences, Inc.
Sector
Industry
CEO
Andrew R. Robbins
Website
Headquarters
Waltham
Founded
2014
FIGI
BBG007DHZQR7
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of COGT is 7.61 USD — it has decreased by −2.45% in the past 24 hours. Watch Cogent Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cogent Biosciences, Inc. stocks are traded under the ticker COGT.
COGT stock has fallen by −3.33% compared to the previous week, the month change is a −20.78% fall, over the last year Cogent Biosciences, Inc. has showed a 25.16% increase.
We've gathered analysts' opinions on Cogent Biosciences, Inc. future price: according to them, COGT price has a max estimate of 23.00 USD and a min estimate of 10.00 USD. Watch COGT chart and read a more detailed Cogent Biosciences, Inc. stock forecast: see what analysts think of Cogent Biosciences, Inc. and suggest that you do with its stocks.
COGT reached its all-time high on Aug 7, 2018 with the price of 70.64 USD, and its all-time low was 1.18 USD and was reached on Apr 9, 2020. View more price dynamics on COGT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
COGT stock is 4.02% volatile and has beta coefficient of 0.12. Track Cogent Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cogent Biosciences, Inc. there?
Today Cogent Biosciences, Inc. has the market capitalization of 854.98 M, it has increased by 2.88% over the last week.
Yes, you can track Cogent Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Cogent Biosciences, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
COGT earnings for the last quarter are −0.64 USD per share, whereas the estimation was −0.57 USD resulting in a −13.04% surprise. The estimated earnings for the next quarter are −0.59 USD per share. See more details about Cogent Biosciences, Inc. earnings.
Cogent Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
COGT net income for the last quarter is −70.63 M USD, while the quarter before that showed −58.95 M USD of net income which accounts for −19.82% change. Track more Cogent Biosciences, Inc. financial stats to get the full picture.
No, COGT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 164.00 employees. See our rating of the largest employees — is Cogent Biosciences, Inc. on this list?
Like other stocks, COGT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cogent Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cogent Biosciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cogent Biosciences, Inc. stock shows the sell signal. See more of Cogent Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.